Mer­ck and Ei­sai to stop Keytru­da plus Lenvi­ma tri­al in head and neck can­cer af­ter dis­ap­point­ing in­ter­im re­sults

Mer­ck and Ei­sai an­nounced Fri­day morn­ing that they plan to close a Phase III study of the com­bi­na­tion of Keytru­da and Ei­sai’s ty­ro­sine ki­nase in­hibitor Lenvi­ma in head and neck squa­mous cell car­ci­no­ma.

The com­pa­nies said the de­ci­sion came af­ter a sec­ond in­ter­im analy­sis in which the com­bo did not im­prove over­all sur­vival (OS) com­pared to Keytru­da and place­bo in pa­tients whose tu­mors ex­press PD-L1. Since the study was not like­ly to meet its pri­ma­ry OS end­point, the two com­pa­nies de­cid­ed to stop it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER